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11C-Flumazenil positron emission 
 tomography demonstrates reduction 
of both global and local cerebral 
 benzodiazepine receptor binding 
in a patient with Stiff Person Syndrome
Introduction
Recent evidence suggests that the Stiff Person Syndrome 
(SPS) is caused by an autoimmunologically mediated 
process [1]. In up to 50 % of cases, SPS occurs in associa-
tion with other autoimmune diseases, such as Diabetes 
mellitus type 1, Grave’s disease, Hashimoto-Thyreoiditis 
and pernicious anemia, or as a paraneoplastic syndrome 
[9]. In approximately 80 % of SPS patients, autoantibod-
ies against glutamic acid decarboxylase (GAD-Ab) exist, 
suggesting an autoimmune-mediated impairment of γ-
aminobutyric acid (GABA)ergic neuronal function as a 
key mechanism underlying muscle hyperactivity [10]. 
However, the pathogenetic role of GAD-Ab in SPS re-
mains to be further elucidated. We present the case of a 
female patient with SPS and reduced global and local 
cortical and subcortical benzodiazepine receptor bind-
ing detected with [11C]flumazenil (FMZ) positron emis-
sion tomography (PET). FMZ is a radioligand which 
binds to the central benzodiazepine receptor which is 
co-localized with the GABA-A receptor. FMZ binds to a 
subunit of the postsynaptic GABAergic complex and is 
a reliable marker of neuronal integrity [4].
Case presentation
A 53-year-old woman presented with increased rigidity 
of her legs, particularly after long sitting or standing 
times and after exposure to coldness with symptom on-
set about one year prior to admission. She had a history 
of musicogenic reflex epilepsy for 30 years, treated with 
phenytoine 300 mg daily, and no more than two seizures 
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■ Abstract  Stiff Person Syndrome 
(SPS) is a rare autoimmune disor-
der associated with antibodies 
against glutamic acid decarboxyl-
ase (GAD-Ab), the key enzyme in 
γ-aminobutyric acid synthesis 
(GABA). In order to investigate the 
role of cerebral benzodiazepine-
 receptor binding in SPS, we per-
formed [11C]flumazenil (FMZ) 
 positron emission tomography 
(PET) in a female patient with SPS 
compared to nine healthy controls. 
FMZ is a radioligand to the post-
synaptic central benzodiazepine 
receptor which is co-localized with 
the GABA-A receptor. In the SPS 
patient, we found a global reduc-
tion of cortical FMZ binding. In 
addition, distinct local clusters of 
reduced radiotracer binding were 
observed. These data provide first 
in vivo evidence for a reduced 
postsynaptic GABA-A receptor 
availability which may reflect the 
loss of GABAergic neuronal inhibi-
tion in SPS.
■ Key words  [11C]flumazenil PET 
· GABA-A-receptor-associated 
 protein · antibodies against 
 glutamic acid decarboxylase · 
GABA-A receptor
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per year. Additionally, she was treated for restless legs 
syndrome with 6 mg ropinirole at night and for hypo-
thyreoidism with 150 μg levothyroxine per day. Her fam-
ily history was unremarkable. On examination, she had 
pronounced muscular rigidity of both legs which in-
creased dramatically after sitting or standing for a long 
time and subsequent to coldness. Her walking distance 
was reduced and her gait was unstable. Neurological ex-
amination was otherwise normal. Laboratory testing 
revealed markedly increased serum GAD-Ab (> 300 U/
l), a decreased vitamin B12 level (106 mg/l), autoanti-
bodies against parietal cells, decreased TSH (0.24 mU/l) 
and ferritin (12 μg/l) levels and an increased homocys-
teine level (23.3 μmol/l). Amphiphysin antibodies were 
absent. EMG showed simultaneous motor unit activity 
in agonist and antagonist lower limb muscles. EEG, so-
matosensory and motor evoked potentials, as well as 
cerebral magnetic resonance imaging (MRI) were nor-
mal (see Fig. 1). MRI of the spine revealed a herniated 
vertebral disc of the cervical segment 6/7 without rele-
vant spinal cord compression. Diagnosis of SPS was 
made and a pulse of 500 mg intravenous methylpred-
nisolone was administered for five days, subsequently 
reduced to an oral methylprednisolone maintenance 
dose of 20 mg daily [9]. In addition, the substitution of 
iron and vitamin B12 was initiated. Under immunomod-
ulatory treatment, motor symptoms improved slowly. 
Symptomatic therapy with antispastic drugs or benzo-
diazepines was not necessary.
Methods
After obtaining written informed consent, the patient was investi-
gated before initiation of the immunomodulatory treatment with 
FMZ-PET in resting state using an ECAT HRRT scanner (Siemens/
CTI, Knoxville, TN, USA). All medication was discontinued 12 hours 
before scanning. The individual patient data were compared to those 
of 9 healthy volunteers (2 female and 7 male; mean age, 61.4 y; range, 
29–74 y) without central nervous disease and without any medication 
with central nervous action who were examined either on the ECAT 
EXACT HR or on the ECAT EXACT HRRT scanner. 20 mCi (740 MBq) 
of FMZ were injected intravenously, and the accumulation of FMZ 
was recorded for 60 minutes by dynamic serial scanning. 
 To ensure comparability of the PET data, all images underwent the 
same processing steps including Gaussian smoothing (12 mm width) 
and spatial normalization by statistical parametric mapping (SPM2; 
Wellcome Department of Imaging Neuroscience, University College 
London, U.K.). To generate parametric images, a proportional scaling 
of cortical FMZ binding relative to white matter activity was per-
formed [16]. The latter was measured using ellipsoid shaped regions 
of interest (ROI) placed in the right oval center in the same x-, y-, and 
z-direction after coregistration of all PET images. From the scaled 
images of all healthy volunteers an average and a standard deviation 
image was derived. This average image was subtracted from the image 
of the patient and the difference image was divided by the control’s 
standard deviation image on voxel-by-voxel basis, thus, yielding a z-
transformed image of the patient’s FMZ-binding. This image is dis-
played in a discrete color scale with one interval representing 0.5 z-
scores (see Fig. 1).
 All voxels with z-scores below –2 were regarded as showing a FMZ 
tracer binding out of the normal range. The Talairach coordinates of 
maximum significant abnormal voxels with reduced FMZ tracer 
binding were identified and labeled with the respective Brodmann 
areas (BA) using the Talairach & Tournoux Atlas [19].
Results
After z-transformation, a global decrease of cerebral 
FMZ binding was found in the SPS patient (Fig. 1). The 
mean z-score was –0.56 ± 0.49 in a circular ROI includ-
ing the whole brain at the level with the best representa-
tion of the basal ganglia. In addition, significant clusters 
of locally reduced FMZ binding with a z-score below –2 
were found in the right primary motor cortex (BA 4), 
Fig. 1  Transaxial T2-weighted MR im-
ages of the SPS patient. No pathology 
was observed (upper panel). Transaxial 
PET z-maps of the FMZ binding of the 
SPS patient on voxel-by-voxel basis 
(lower panel). Voxels are shown for 
z-score thresholds ranging from 0 to –4 
(by steps of 0.5; Bronson color scale). 
Significant changes were defined at a 
z-threshold below –2
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right supplementary motor area (BA 6), right orbito-
frontal cortex (BA 10, 11, 47), right middle occipital cor-
tex (BA 19), right parahippocampal gyrus and left cin-
gulate gyrus (BA 28, 31), left supramarginal area (BA 40) 
and in the right and left caudate head. Infratentorial 
 areas with reduced FMZ binding were found in the 
 cerebellar tonsils and in the vermis (Fig. 1, Table 1).
Discussion
The key PET finding in our SPS patient is a global reduc-
tion of cortical FMZ binding together with significant 
clusters of locally reduced tracer binding compared to a 
control group. Our data suggest that cerebral GABA-A 
receptor binding is impaired both globally and locally in 
SPS which might substantially contribute to the disinhi-
bition of neuronal activity with subsequent muscular 
hyperactivity, rigidity and stiffness. Interestingly, the co-
incident startle type musicogenic epilepsy might also 
result from an impaired GABAergic neuronal inhibition 
as suggested by previous animal studies [3].
FMZ is a ligand which binds to the central benzodi-
azepine receptor which is co-localized with the GABA-A 
receptor and a subunit of the postsynaptic GABAergic 
complex [11]. FMZ has been shown to be a reliable 
marker of cortical neuronal loss in various brain disor-
ders, such as epilepsy [18], Alzheimer’s disease [12], 
acute vegetative state [15] and stroke [5]. However, corti-
cal neuronal loss is not a feature of SPS in neuropatho-
logic studies [11] and was also ruled out in our SPS pa-
tient by a normal brain MRI (Fig. 1). Therefore, the 
reduced FMZ binding is best explained by reduced 
GABA-A receptor density on neuronal cell surfaces re-
sulting in a reduced number of binding sites for the 
 radiotracer. Our finding is of special interest in the light 
of a recent study conducted by Raju and colleagues 
 describing autoimmunity in SPS patients against 
the GABA-A-receptor-associated protein (GABARAP), 
which is responsible for the stability and surface expres-
sion of the GABA-A receptor [14]. The authors con-
cluded that GABARAP acts as an autoantigen in SPS 
patients in which antibody-mediated blocking results in 
a decreased availability of central postsynaptic benzodi-
azepine receptors. Our FMZ-PET data are in line with 
this hypothesis and provide, therefore, in vivo evidence 
for the involvement of postsynaptic GABA-A receptor 
dysfunction in the pathophysiology of muscle hyperac-
tivity in SPS patients. 
One possible explanation for the global reduction of 
brain FMZ binding in our SPS patient might be a sys-
temic autoimmune disease process with antibodies 
against GABARAP and a resulting ubiquitous reduction 
of neuronal GABA-A receptor surface expression. In ad-
dition, however, clusters with local FMZ binding reduc-
tion were found in motor and premotor cortices which 
are likely to be related to the development of motor 
symptoms in SPS. These findings are fully compatible 
with previous studies using MR spectroscopy: Levy and 
colleagues demonstrated decreased GABA levels in the 
sensorimotor, cingulate and occipital cortex [7]. Another 
PET study by Perani and colleagues also reported an ex-
tensively decreased FMZ binding bilaterally in the pre-
motor cortex of two SPS patients versus controls [13]. 
Despite the fact that the reasons for a regional selectivity 
of GABA transmitter dysfunction in SPS are currently 
unknown, the authors proposed a selective involvement 
of premotor-motor cortices due to the high demand of 
modulator control and a finely tuned GABAergic trans-
mission in these regions [6]. 
From a methodological point of view, hypothetical 
drug effects on our PET findings have to be considered. It 
has to be pointed out that an affection of GABA-A recep-
tors due to drugs included in the medication of the pa-
tient (phenytoine, ropinirole and levothyroxine) has pre-
viously been described, but a significant effect related to 
the benzodiazepine receptor or a local receptor selectiv-
ity was not observed [2, 8, 17]. Moreover, there is no evi-
dence available for long-term alterations of cerebral ben-
zodiazepine receptor binding due to any of these drugs. 
In conclusion, our FMZ-PET data provide in vivo 
evidence that postsynaptic benzodiazepine receptor 
dysfunction contributes to the reduced GABAergic neu-
ronal inhibition in SPS. From a clinical point of view, a 
reduced availability of GABA receptors in motor-related 
areas might be a major pathophysiological determinant 
of muscular hyperactivity and stiffness in SPS. There-
fore, FMZ-PET seems to be a suitable tool to investigate 
the pathogenetic role of cerebral GABA transmitter dys-
function in SPS. 








 4 right precentral gyrus 36, –17, 39 –3.86
 6 right precentral gyrus 57, 5, 9 –3.67
 9 right superior frontal gyrus 9, 61, 36 –2.78
 10“ right medial frontal gyrus 12, 35, –14 –2.81
 11 right inferior frontal gyrus 13, 35, –16 –2.65
 19 right middle occipital gyrus 27, –80, 11 –2.45
 28 right parahippocampal gyrus 20, –10, –21 –2.78
 31 left cingulate gyrus –9, –22, 40 –3.25
 40 left supramarginal gyrus –31, –44, 35 –2.95
 47 right middle frontal gyrus 39, 35, –7 –2.25
 – right caudate head 9, 6, 6 –2.44
 – left caudate head –8, 7, 6 –2.35
 – right cerebellar tonsil 5, –53, –38 –2.26
 – right vermis 7, –85, –18 –2.69
 – left cerebellar tonsil –24, –59, –34 –2.16
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